335 related articles for article (PubMed ID: 29785076)
1. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
Pacifico L; Andreoli GM; D'Avanzo M; De Mitri D; Pierimarchi P
World J Gastroenterol; 2018 May; 24(19):2073-2082. PubMed ID: 29785076
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.
Vachliotis ID; Polyzos SA
Curr Obes Rep; 2023 Jun; 12(2):147-162. PubMed ID: 37208545
[TBL] [Abstract][Full Text] [Related]
3. Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Lu J; Liu F; Liu D; Du H; Hao J; Yang X; Cui W
Exp Biol Med (Maywood); 2016 Jun; 241(11):1237-49. PubMed ID: 26908571
[TBL] [Abstract][Full Text] [Related]
4. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
5. Circulating mRNA and plasma levels of osteoprotegerin and receptor activator of NF-κB ligand in nonalcoholic fatty liver disease.
Nikseresht M; Azarmehr N; Arya A; Alipoor B; Fadaei R; Khalvati B; Abidi H; Doustimotlagh AH
Biotechnol Appl Biochem; 2021 Dec; 68(6):1243-1249. PubMed ID: 33010062
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling.
Ding Z; Shi H; Yang W
Pharmacology; 2019; 103(3-4):163-172. PubMed ID: 30695776
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
8. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
9. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
11. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.
Kelesidis T; Currier JS; Yang OO; Brown TT
AIDS Rev; 2014; 16(3):123-33. PubMed ID: 25102334
[TBL] [Abstract][Full Text] [Related]
12. [The expression of receptor activator nuclear factor-kappaB ligand and osteoprotegerin in cholesteatoma].
Ma Y; Ye S
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Apr; 22(7):293-5. PubMed ID: 18589796
[TBL] [Abstract][Full Text] [Related]
13. OPG/RANK/RANKL signaling system and its significance in nephrology.
Klejna K; Naumnik B; Gasowska K; Myśliwiec M
Folia Histochem Cytobiol; 2009; 47(2):199-206. PubMed ID: 19995704
[TBL] [Abstract][Full Text] [Related]
14. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
[TBL] [Abstract][Full Text] [Related]
15. RANK/RANKL/OPG system in the intervertebral disc.
Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
[TBL] [Abstract][Full Text] [Related]
16. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
Pepene CE; Ilie IR; Marian I; Duncea I
Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
[TBL] [Abstract][Full Text] [Related]
17. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of nuclear factor-kappa B ligand and correlation factor in the tissue of otitis media with cholesteatoma].
Xia M; Ding S; Zhang H; Liu F; Yin H; Xu A
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Apr; 21(7):315-7. PubMed ID: 17580719
[TBL] [Abstract][Full Text] [Related]
20. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis.
Pilichou A; Papassotiriou I; Michalakakou K; Fessatou S; Fandridis E; Papachristou G; Terpos E
Clin Biochem; 2008 Jun; 41(9):746-9. PubMed ID: 18355453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
